Juno Therapeutics (NASDAQ:JUNO) has been given a $56.00 price objective by equities research analysts at Maxim Group in a research report issued on Wednesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price objective indicates a potential upside of 22.40% from the stock’s previous close.

The analysts wrote, “The American Society of Hematology (ASH) is now over, and while we saw bluebird’s (BLUE – $190.95 – Hold) valuation rise to over $9B on strong data in CAR-T and gene therapy, Juno’s valuation has seen a retracement from its pre- ASH peak of $7B, to $5B on what is incremental data for lead CAR candidate JCAR017.””

Several other research analysts also recently issued reports on the company. Raymond James Financial reaffirmed a “buy” rating on shares of Juno Therapeutics in a research note on Monday. Wells Fargo & Company downgraded Juno Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Zacks Investment Research downgraded Juno Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. Cowen reaffirmed a “buy” rating on shares of Juno Therapeutics in a research note on Friday, November 3rd. Finally, Leerink Swann reaffirmed an “in-line” rating and set a $56.00 price target (up previously from $34.00) on shares of Juno Therapeutics in a research note on Thursday, November 2nd. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the company’s stock. Juno Therapeutics has a consensus rating of “Hold” and an average target price of $45.48.

Shares of Juno Therapeutics (NASDAQ JUNO) opened at $45.75 on Wednesday. Juno Therapeutics has a 1 year low of $17.52 and a 1 year high of $63.45. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01.

Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.07. The business had revenue of $44.80 million during the quarter, compared to the consensus estimate of $18.12 million. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The business’s revenue was up 115.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.57) EPS. equities analysts expect that Juno Therapeutics will post -4.02 earnings per share for the current year.

In related news, EVP Robert Azelby sold 6,666 shares of the business’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $54.95, for a total value of $366,296.70. Following the completion of the transaction, the executive vice president now owns 79,998 shares of the company’s stock, valued at approximately $4,395,890.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Sunil Agarwal sold 7,285 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $44.76, for a total transaction of $326,076.60. The disclosure for this sale can be found here. Insiders sold a total of 41,951 shares of company stock valued at $1,950,133 in the last three months. 15.08% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in the stock. Boyer & Corporon Wealth Management LLC increased its stake in shares of Juno Therapeutics by 0.9% during the 2nd quarter. Boyer & Corporon Wealth Management LLC now owns 12,579 shares of the biopharmaceutical company’s stock valued at $484,000 after acquiring an additional 115 shares during the last quarter. Utah Retirement Systems increased its stake in shares of Juno Therapeutics by 1.8% during the 2nd quarter. Utah Retirement Systems now owns 11,600 shares of the biopharmaceutical company’s stock valued at $347,000 after acquiring an additional 200 shares during the last quarter. State of Wisconsin Investment Board increased its stake in shares of Juno Therapeutics by 1.7% during the 2nd quarter. State of Wisconsin Investment Board now owns 12,562 shares of the biopharmaceutical company’s stock valued at $375,000 after acquiring an additional 210 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Juno Therapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 228 shares during the last quarter. Finally, Legal & General Group Plc increased its stake in shares of Juno Therapeutics by 5.9% during the 2nd quarter. Legal & General Group Plc now owns 5,470 shares of the biopharmaceutical company’s stock valued at $210,000 after acquiring an additional 306 shares during the last quarter. 70.37% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/12/13/maxim-group-reiterates-56-00-price-target-for-juno-therapeutics-juno.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.